PureTech reports FDA Phase 1 end-of-phase meeting success
PureTech says it completed an FDA End-of-Phase 1 meeting and received Fast Track designation for LYT-200 in relapsed/refractory high-risk myelodysplastic syndromes (HR-MDS).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.